JP2003238444A5 - - Google Patents

Download PDF

Info

Publication number
JP2003238444A5
JP2003238444A5 JP2002093288A JP2002093288A JP2003238444A5 JP 2003238444 A5 JP2003238444 A5 JP 2003238444A5 JP 2002093288 A JP2002093288 A JP 2002093288A JP 2002093288 A JP2002093288 A JP 2002093288A JP 2003238444 A5 JP2003238444 A5 JP 2003238444A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ang
antagonist
ace inhibitor
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002093288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003238444A (ja
Filing date
Publication date
Priority claimed from GBGB0020691.2A external-priority patent/GB0020691D0/en
Priority to GBGB0020691.2A priority Critical patent/GB0020691D0/en
Priority to DE10108215A priority patent/DE10108215A1/de
Priority to BR0113321-7A priority patent/BR0113321A/pt
Priority to IL15393701A priority patent/IL153937A0/xx
Priority to PCT/EP2001/009428 priority patent/WO2002015891A2/en
Priority to CA002415788A priority patent/CA2415788A1/en
Priority to EP01976082A priority patent/EP1313468A2/en
Priority to CN01814414A priority patent/CN1447691A/zh
Priority to SK206-2003A priority patent/SK2062003A3/sk
Priority to AU2001295465A priority patent/AU2001295465B2/en
Priority to CZ2003534A priority patent/CZ2003534A3/cs
Priority to JP2002093288A priority patent/JP2003238444A/ja
Priority to CA002372785A priority patent/CA2372785A1/en
Application filed filed Critical
Priority to US10/354,713 priority patent/US20030171415A1/en
Priority to BG107558A priority patent/BG107558A/bg
Priority to NO20030761A priority patent/NO20030761D0/no
Publication of JP2003238444A publication Critical patent/JP2003238444A/ja
Publication of JP2003238444A5 publication Critical patent/JP2003238444A5/ja
Pending legal-status Critical Current

Links

JP2002093288A 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物 Pending JP2003238444A (ja)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0020691.2A GB0020691D0 (en) 2000-08-22 2000-08-22 Pharmaceutical combination
DE10108215A DE10108215A1 (de) 2000-08-22 2001-02-20 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym
AU2001295465A AU2001295465B2 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
IL15393701A IL153937A0 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
PCT/EP2001/009428 WO2002015891A2 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
CA002415788A CA2415788A1 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
EP01976082A EP1313468A2 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
CN01814414A CN1447691A (zh) 2000-08-22 2001-08-16 血管紧张素ⅱ拮抗剂与血管紧张素ⅰ转换酶抑制剂的药物组合物
SK206-2003A SK2062003A3 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors
BR0113321-7A BR0113321A (pt) 2000-08-22 2001-08-16 Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i
CZ2003534A CZ2003534A3 (cs) 2000-08-22 2001-08-16 Farmaceutický prostředek
JP2002093288A JP2003238444A (ja) 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物
CA002372785A CA2372785A1 (en) 2000-08-22 2002-02-21 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
US10/354,713 US20030171415A1 (en) 2000-08-22 2003-01-30 Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
BG107558A BG107558A (bg) 2000-08-22 2003-02-14 Фармацевтична комбинация от ангиотензин ii антагонисти ii ангиотензин i конвертиращи ензимни инхибитори
NO20030761A NO20030761D0 (no) 2000-08-22 2003-02-18 Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0020691.2A GB0020691D0 (en) 2000-08-22 2000-08-22 Pharmaceutical combination
DE10108215A DE10108215A1 (de) 2000-08-22 2001-02-20 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym
CA002372785A CA2372785A1 (en) 2000-08-22 2002-02-21 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
JP2002093288A JP2003238444A (ja) 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物

Publications (2)

Publication Number Publication Date
JP2003238444A JP2003238444A (ja) 2003-08-27
JP2003238444A5 true JP2003238444A5 (https=) 2005-08-25

Family

ID=32234234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002093288A Pending JP2003238444A (ja) 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物

Country Status (15)

Country Link
US (1) US20030171415A1 (https=)
EP (1) EP1313468A2 (https=)
JP (1) JP2003238444A (https=)
CN (1) CN1447691A (https=)
AU (1) AU2001295465B2 (https=)
BG (1) BG107558A (https=)
BR (1) BR0113321A (https=)
CA (2) CA2415788A1 (https=)
CZ (1) CZ2003534A3 (https=)
DE (1) DE10108215A1 (https=)
GB (1) GB0020691D0 (https=)
IL (1) IL153937A0 (https=)
NO (1) NO20030761D0 (https=)
SK (1) SK2062003A3 (https=)
WO (1) WO2002015891A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20040248968A1 (en) * 2002-02-20 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
EP2684564A1 (en) 2008-04-17 2014-01-15 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
TR199701121T1 (xx) * 1995-04-07 1998-03-21 Novartis Ag Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri.
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
CA2257946A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Similar Documents

Publication Publication Date Title
JP2003238444A5 (https=)
JP2005041875A5 (https=)
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
JP2009256381A5 (https=)
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
IL148127A (en) Use of ramipril or its pharmaceutical salt to prepare or prevent heart events in high-risk patients without evidence of left ventricular dysfunction
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
IL160643A (en) Orally administrable pharmaceutical dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor and aspirin and a packaged kit
ME02179B (me) Metoda za lečenje atrijalne fibrilacije
EA200401317A1 (ru) Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
JP2011529968A5 (https=)
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
FI4101454T3 (fi) Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon
WO2012176149A1 (en) Treatment of hepatitis c virus
JP2004525940A5 (https=)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2002535367A5 (https=)
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
JP2008503581A5 (https=)
US7625940B2 (en) Method of treating hypertension with a very low dose of chlorthalidone
TNSN07166A1 (en) Composition comprising vlp and amyloid-beta peptide
ME01958B (me) KOMBINACIJA INHIBITORA If STRUJE SINUSNOG NODUSA I INHIBITORA ENZIMA KONVERZIJE ANGIOTENZINA
RU2012136190A (ru) Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента